No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
3252 |
4. Check minimum number of events
Min. number of events
3
|
3252 |
5. Include endpointsNone |
3252 |
6. Filter based on genotype QC (FinnGen only) |
3169 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2
Similar endpoints
↥List of similar endpoints to
Use of disulfiram, acamprosate or naltrexone
based on the number of shared cases.
Similar with more cases:
- Alcohol use disorder, Swedish definition
- Alcohol related diseases and deaths, all endpoints
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 26141 | 6777 | 19291 |
| Only index persons | 24858 | 6542 | 18316 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.45 | 0.19 | 0.54 |
| Only index persons | 0.58 | 0.24 | 0.70 |
| Median age at first event (years) | |||
| Whole population | 42.28 | 42.46 | 42.23 |
| Only index persons | 42.16 | 42.34 | 42.09 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3169 | 1015 | 2154 |
| Unadjusted period prevalence (%) | 0.86 | 0.40 | 1.08 |
| Median age at first event (years) | 42.73 | 41.15 | 43.48 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint ALCO_PRESCRIPTION and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ALCO_PRESCRIPTION | 3.7 [3.31, 4.13] | < 0.001 |
| Birth year | 0.991 [0.98, 1.0] | 0.055 |
During the follow-up period (1.1.1998 — 31.12.2019), 883 out of 6684 females with ALCO_PRESCRIPTION died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ALCO_PRESCRIPTION | 2.635 [2.43, 2.86] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.014 |
During the follow-up period (1.1.1998 — 31.12.2019), 3617 out of 19055 males with ALCO_PRESCRIPTION died.
Mortality risk
Mortality risk for people of age
years, who have ALCO_PRESCRIPTION.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.256% | 0.531% |
| 5 | 1.906% | 3.245% |
| 10 | 4.625% | 7.878% |
| 15 | 8.92% | 14.854% |
| 20 | 15.444% | 24.539% |
Relationships between endpoints
↥Index endpoint: ALCO_PRESCRIPTION – Use of disulfiram, acamprosate or naltrexone
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data